24.78 USD
↘ 0.15 (0.59%)LIVE (AS OF 11:39 AM EDT)
Alumis Inc. Common Stock
ALMSNASDAQ • USD
Market: OPEN
Open?$24.20
High?$25.30
Low?$24.11
Prev. Close?$24.93
Volume?334.5K
Avg. Volume?1.6M
VWAP?$24.65
Rel. Volume?0.21x
Bid / Ask
Bid?$24.72 × 100
Ask?$24.78 × 100
Spread?$0.06
Midpoint?$24.75
Valuation & Ratios
Market Cap?3.2B
Shares Out?123.1M
Float?71.1M
Float %?57.7%
P/E Ratio?N/A
P/B Ratio?10.52
EPS?-$1.91
Dividend?0.00%
Ex-Dividend?N/A
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?4.34Strong
Quick Ratio?4.34Strong
Cash Ratio?1.22Strong
Debt/Equity?0.00Low
ValuationRICHLY VALUED
Score50/100
P/E?N/A▾
P/B?10.52HIGH▾
P/S?131.85HIGH▾
P/FCF?N/A▾
EV/EBITDA?-6.8CHEAP▾
EV/Sales?128.13HIGH▾
Returns & Efficiency
ROE?-80.8%WEAK▾
ROA?-59.1%WEAK▾
Cash Flow & Enterprise
FCF?$-370176000
Enterprise Value?$3.1B
Fundamentals ratios updated end of day
xxx
Related Companies
Loading...
News
Profile
Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.
Address
280 EAST GRAND AVENUE
SOUTH SAN FRANCISCO, CA 94080
Phone: 650-231-6625
SOUTH SAN FRANCISCO, CA 94080
Phone: 650-231-6625